These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 26130305)

  • 21. High-resolution melting effectively pre-screens for TP53 mutations before direct sequencing in patients with diffuse glioma.
    Saito K; Yokogami K; Maekawa K; Sato Y; Yamashita S; Matsumoto F; Mizuguchi A; Takeshima H
    Hum Cell; 2021 Mar; 34(2):644-653. PubMed ID: 33454902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDH Mutation Analysis in Glioma Patients by CADMA Compared with SNaPshot Assay and two Immunohistochemical Methods.
    Urbanovska I; Megova MH; Dwight Z; Kalita O; Uvirova M; Simova J; Tuckova L; Buzrla P; Palecek T; Hajduch M; Dvorackova J; Drabek J
    Pathol Oncol Res; 2019 Jul; 25(3):971-978. PubMed ID: 29556922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
    Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
    Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
    Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
    Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.
    Takano S; Kato Y; Yamamoto T; Liu X; Ishikawa E; Kaneko MK; Ogasawara S; Matsuda M; Noguchi M; Matsumura A
    Brain Tumor Pathol; 2015 Jul; 32(3):169-75. PubMed ID: 25652153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
    Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q
    Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.
    Das BR; Tangri R; Ahmad F; Roy A; Patole K
    Asian Pac J Cancer Prev; 2013; 14(12):7261-4. PubMed ID: 24460285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples.
    Avsar T; Sursal A; Turan G; Yigit BN; Altunsu D; Cantasir K; Duyu G; Bayoumi AB; Yapicier O; Acar M; Kilic T
    Mol Diagn Ther; 2020 Jun; 24(3):327-338. PubMed ID: 32274701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
    Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
    Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
    Ishizawa K; Hirose T; Sugiyama K; Kageji T; Nobusawa S; Homma T; Komori T; Sasaki A
    Clin Neuropathol; 2012; 31(2):67-76. PubMed ID: 22385787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
    Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
    Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
    Gondim DD; Gener MA; Curless KL; Cohen-Gadol AA; Hattab EM; Cheng L
    Appl Immunohistochem Mol Morphol; 2019; 27(10):722-725. PubMed ID: 30358614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.
    Jabbar KJ; Luthra R; Patel KP; Singh RR; Goswami R; Aldape KD; Medeiros LJ; Routbort MJ
    Am J Surg Pathol; 2015 Apr; 39(4):454-61. PubMed ID: 25634750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid detection of isocitrate dehydrogenase 1 mutation status in glioma based on Crispr-Cas12a.
    Feng Z; Kong D; Jin W; He K; Zhao J; Liu B; Xu H; Yu X; Feng S
    Sci Rep; 2023 Apr; 13(1):5748. PubMed ID: 37029174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma.
    Kanamori M; Kikuchi A; Watanabe M; Shibahara I; Saito R; Yamashita Y; Sonoda Y; Kumabe T; Kure S; Tominaga T
    J Neurosurg; 2014 Jun; 120(6):1288-97. PubMed ID: 24745708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
    Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
    Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
    Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I
    Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.